Kristin VanderPas

Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.

Cooley advised the underwriters in the upsized $345.1 million initial public offering of Apogee Therapeutics, a biotechnology company.

Cooley advised the underwriters in IGM Biosciences’ $97.5 million public offering of 9,000,000 shares of non-voting common stock and 3,187,500 shares of voting common stock, each at the public offering price of $8.00 per share, as well as a $22.5 million concurrent private placement. IGM is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, autoimmune and inflammatory diseases, and infectious diseases. Denny Won, Kristin VanderPas and Charlie Kim led the Cooley team.

Cooley advised TPB Acquisition Corporation I, a special purpose acquisition company sponsored by The Production Board, in its business combination agreement that will result in Lavoro Limited, a leading agricultural inputs retailer in Latin America, becoming a US publicly listed company with an implied initial enterprise value of approximately $1.2 billion.

Cooley advised the underwriters in Erasca’s $100 million follow-on offering of 15,384,616 shares of common stock at a public offering price of $6.50 per share. Erasca is a clinical-stage biopharmaceutical company discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Partners Charlie Kim, Kristin VanderPas and Denny Won led the Cooley team.